CUVL · Clinuvel Pharmaceuticals Ltd ADR
United States · RS rating 23 · As of 2026-11-03
| Price | 5.08 USD |
|---|---|
| 1-day change | +3.4% |
| RS rating (overall / 1M / 3M / 12M) | 23 / 33 / 29 / 31 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 9 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +42.0% |
| Market cap (USD) | $361.6M |